[go: up one dir, main page]

DK1635863T3 - Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål - Google Patents

Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål

Info

Publication number
DK1635863T3
DK1635863T3 DK04776760.3T DK04776760T DK1635863T3 DK 1635863 T3 DK1635863 T3 DK 1635863T3 DK 04776760 T DK04776760 T DK 04776760T DK 1635863 T3 DK1635863 T3 DK 1635863T3
Authority
DK
Denmark
Prior art keywords
compositions
prophylactic
enhancing
mhc class
immune responses
Prior art date
Application number
DK04776760.3T
Other languages
English (en)
Inventor
Adrian Ion Bot
Xiping Liu
Kent Andrew Smith
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of DK1635863T3 publication Critical patent/DK1635863T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04776760.3T 2003-06-17 2004-06-17 Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål DK1635863T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47939303P 2003-06-17 2003-06-17
PCT/US2004/019546 WO2005002621A2 (en) 2003-06-17 2004-06-17 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes

Publications (1)

Publication Number Publication Date
DK1635863T3 true DK1635863T3 (da) 2010-11-22

Family

ID=33563795

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04776760.3T DK1635863T3 (da) 2003-06-17 2004-06-17 Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål

Country Status (12)

Country Link
US (1) US20050079152A1 (da)
EP (3) EP2246067B1 (da)
JP (2) JP5127224B2 (da)
AT (1) ATE476196T1 (da)
AU (1) AU2004253479B9 (da)
CA (1) CA2529057A1 (da)
DE (1) DE602004028468D1 (da)
DK (1) DK1635863T3 (da)
ES (1) ES2350043T3 (da)
MX (1) MXPA05013973A (da)
PL (1) PL1635863T3 (da)
WO (1) WO2005002621A2 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
MXPA05004588A (es) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP2332971B1 (en) * 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
JP2008503494A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 診断方法を治療方法と統合することによる免疫療法の効力改善
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
KR101294290B1 (ko) * 2004-12-29 2013-08-07 맨카인드 코포레이션 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법
EP2351576A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US7511119B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PRAME peptide analogues
KR20080033271A (ko) * 2005-06-17 2008-04-16 맨카인드 코포레이션 암종을 위한 다가 동반이행 및 증폭형 면역치료제
CA2612516C (en) * 2005-06-17 2015-03-24 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
EP1792627A1 (en) * 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
KR20090016704A (ko) 2006-06-15 2009-02-17 노파르티스 아게 보조제-보존 수회-투여 인플루엔자 접종 요법
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080014211A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2129389B1 (en) 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN106220721B (zh) * 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
AU7983198A (en) * 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
IL133912A0 (en) * 1997-07-10 2001-04-30 Ctl Immunotherapies Corp A method of inducing ctl response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
WO2001030382A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
EP1372736A4 (en) * 2001-03-07 2004-11-17 Mannkind Corp PREPARATIONS AGAINST CANCER FORMATION
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CA2394503A1 (en) 2001-07-23 2003-01-23 Research In Motion Limited System and method for pushing information to a mobile device
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
EP1450854A2 (en) * 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
US20060257416A1 (en) * 2003-06-13 2006-11-16 Palmowski J M Materials and methods for improved vaccination
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Also Published As

Publication number Publication date
ATE476196T1 (de) 2010-08-15
DE602004028468D1 (de) 2010-09-16
EP2246067A3 (en) 2011-07-13
EP2246067B1 (en) 2017-02-15
PL1635863T3 (pl) 2011-01-31
EP1635863A2 (en) 2006-03-22
AU2004253479B9 (en) 2011-10-06
US20050079152A1 (en) 2005-04-14
WO2005002621A3 (en) 2005-08-04
JP2013028619A (ja) 2013-02-07
EP2356999A1 (en) 2011-08-17
AU2004253479B2 (en) 2011-09-01
JP5127224B2 (ja) 2013-01-23
EP2246067A2 (en) 2010-11-03
AU2004253479A1 (en) 2005-01-13
WO2005002621A2 (en) 2005-01-13
ES2350043T3 (es) 2011-01-17
MXPA05013973A (es) 2006-03-02
EP1635863B1 (en) 2010-08-04
JP2007523863A (ja) 2007-08-23
CA2529057A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DK1326633T3 (da) Sammensætning omfattende immunogene mikropartikler
ATE426412T1 (de) Adjuvante influenza-vakzine
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2007024941A3 (en) Polyvalent vaccine
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
WO2004030608A3 (en) Nanoemulsion vaccines
DK1751289T3 (da) TC-83-afledte alfavirus-vektorer, partikler og fremgangsmåder
WO2005037190A3 (en) Multiplex vaccines
NO20072253L (no) Forbedrede vaksiner
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
MY143347A (en) Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
WO2005120564A3 (en) Vaccine compositions and methods
WO2004058188A3 (en) Vaccine compositions and methods
GB2444676A (en) Adjuvanted vaccine
DK1183044T3 (da) Adjuvanskombinationer til immunisering og vacciner
WO2004101737A3 (en) A novel adjuvant capable of specifically activating the adaptive immune response
WO2003084988A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope